JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (66) Citing Articles via Google Scholar Google Scholar Articles by Montgomery, L. L. Articles by Borgen, P. I. Search for Related Content PubMed PubMed Citation Articles by Montgomery, L. L. Articles by Borgen, P. I. Related Collections Pharmacology

---

ANESTHETIC PHARMACOLOGY

Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer

Leslie L. Montgomery, MD^*, Alisa C. Thorne, MD, Kimberly J. Van Zee, MS MD^*, Jane Fey, MPH^*, Alexandra S. Heerdt, MD MPH^*, Mary Gemignani, MD^*, Elisa Port, MD^*, Jeanne Petrek, MD^*, Hiram S. Cody, III, MD^*, and Patrick I. Borgen, MD^*

*Breast Service, Department of Surgery, and Department of Anesthesia, Memorial Sloan-Kettering Cancer Center, New York, New York

Address correspondence and reprint requests to Leslie L. Montgomery, MD, MSKCC-MRI 1026, 1275 York Ave., New York, NY 10021. Address e-mail to montgoml{at}mskcc.org

In the United States, identification of the sentinel lymph node (SLN) requires the use of ^99mTc-labeled colloid, 1% isosulfan blue dye, or both to trace the lymphatic drainage of a given neoplasm. We report our experience with adverse reactions to isosulfan blue dye during SLN mapping in breast cancer. A chart review of the breast cancer SLN database was performed; it included 2392 sequential patients who underwent SLN biopsy involving isosulfan blue dye at Memorial Sloan-Kettering Cancer Center from September 12, 1996, to August 17, 2000. Thirty-nine of 2392 patients (1.6%) had a documented allergic reaction during the mapping procedure. Most reactions (69%) produced urticaria, blue hives, a generalized rash, or pruritus. The incidence of hypotensive reactions was 0.5%. Although anaphylaxis after the injection of isosulfan blue dye is rare, this article highlights the need to suspect anaphylaxis when hemodynamic instability occurs after the injection of this compound. Our experience indicates that bronchospasm and respiratory compromise are unusual and that most patients do not require emergent intubation and can be managed with short-term pressor support. In addition, our data indicate that patients with a sulfa allergy do not display a cross-sensitivity to isosulfan blue dye.

IMPLICATIONS: We report the largest single-institution review of adverse reactions to injection of isosulfan blue dye during sentinel lymph node mapping in breast cancer. Bronchospasm and respiratory compromise are unusual, and most patients can be treated with short-term pressor support. Patients with a sulfa allergy do not display a cross-sensitivity to isosulfan blue dye.

This article has been cited by other articles:

				G. H. Lyman, K. J. Van Zee, and S. B. Edge Impact and Remaining Challenges in the Use of Sentinel Lymph Node Biopsy in Early-stage Breast Cancer ASCO Educational Book, January 1, 2009; 2009(1): 346 - 353. [Abstract] [Full Text] [PDF]

				Y. Liu, C. Truini, and S. Ariyan A Randomized Study Comparing the Effectiveness of Methylene Blue Dye with Lymphazurin Blue Dye in Sentinel Lymph Node Biopsy for the Treatment of Cutaneous Melanoma Ann. Surg. Oncol., September 1, 2008; 15(9): 2412 - 2417. [Abstract] [Full Text] [PDF]

				S. K. Somasundaram, D. W. Chicken, and M. R. S. Keshtgar Detection of the sentinel lymph node in breast cancer Br. Med. Bull., January 3, 2008; (2008) ldm032v1. [Abstract] [Full Text] [PDF]

				L. G. Wilke, L. M. McCall, K. E. Posther, P. W. Whitworth, D. S. Reintgen, A. M. Leitch, S. G. A. Gabram, A. Lucci, C. E. Cox, K. K. Hunt, et al. Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial Ann. Surg. Oncol., April 1, 2006; 13(4): 491 - 500. [Abstract] [Full Text] [PDF]

				G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]

				A. C. Degnim, K. Oh, V. M. Cimmino, K. M. Diehl, A. E. Chang, L. A. Newman, and M. S. Sabel Is Blue Dye Indicated for Sentinel Lymph Node Biopsy in Breast Cancer Patients With a Positive Lymphoscintigram? Ann. Surg. Oncol., September 1, 2005; 12(9): 712 - 717. [Abstract] [Full Text] [PDF]

				M Currie, R K Kerridge, A K Bacon, and J A Williamson Crisis management during anaesthesia: anaphylaxis and allergy Qual. Saf. Health Care, June 1, 2005; 14(3): e19 - e19. [Abstract] [Full Text] [PDF]

				J. E. Mendez, J. V. Fey, H. Cody, P. I. Borgen, and L. M. Sclafani Can Sentinel Lymph Node Biopsy Be Omitted in Patients With Favorable Breast Cancer Histology? Ann. Surg. Oncol., January 1, 2005; 12(1): 24 - 28. [Abstract] [Full Text] [PDF]

				H. Osaka, M. Yashiro, T. Sawada, K. Katsuragi, and K. Hirakawa Is a Lymph Node Detected by the Dye-Guided Method a True Sentinel Node in Gastric Cancer? Clin. Cancer Res., October 15, 2004; 10(20): 6912 - 6918. [Abstract] [Full Text] [PDF]

				A. D. Axon and J. M. Hunter Editorial III: Anaphylaxis and anaesthesia--all clear now? Br. J. Anaesth., October 1, 2004; 93(4): 501 - 504. [Full Text] [PDF]

				T. A. King, J. V. Fey, K. J. Van Zee, A. S. Heerdt, M. L. Gemignani, E. R. Port, L. Sclafani, V. Sacchini, J. A. Petrek, H. S. Cody III, et al. A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer Ann. Surg. Oncol., May 1, 2004; 11(5): 535 - 541. [Abstract] [Full Text] [PDF]

				C. P. Raut, M. D. Daley, K. K. Hunt, J. Akins, M. I. Ross, S. E. Singletary, G. D. Marshall Jr, F. Meric-Bernstam, G. Babiera, B. W. Feig, et al. Anaphylactoid Reactions to Isosulfan Blue Dye During Breast Cancer Lymphatic Mapping in Patients Given Preoperative Prophylaxis J. Clin. Oncol., February 1, 2004; 22(3): 567 - 568. [Full Text] [PDF]

				H. S. Cody III Sentinel Lymph Node Biopsy for Breast Cancer: Does Anybody Not Need One? Ann. Surg. Oncol., December 1, 2003; 10(10): 1131 - 1132. [Full Text] [PDF]

				I. Bedrosian, D. Bedi, H. M. Kuerer, B. D. Fornage, L. Harker, M. I. Ross, F. C. Ames, S. Krishnamurthy, B. S. Edeiken-Monroe, F. Meric, et al. Impact of Clinicopathological Factors on Sensitivity of Axillary Ultrasonography in the Detection of Axillary Nodal Metastases in Patients With Breast Cancer Ann. Surg. Oncol., November 1, 2003; 10(9): 1025 - 1030. [Abstract] [Full Text] [PDF]

				J. Sprung, M. J. Tully, and A. Ziser Anaphylactic Reactions to Isosulfan Blue Dye During Sentinel Node Lymphadenectomy for Breast Cancer Anesth. Analg., April 1, 2003; 96(4): 1051 - 1053. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999